Clinical trials in Veldhoven – page 6

529 clinical trials in Veldhoven, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Veldhoven at a glance

529

clinical trials

Research sites1

Quick filters

529 trials in Veldhoven

Open in trial search

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bempedoic Acid
Sponsor:A. Menarini International Licensing S.A.

Contact Research Centre

Type 2 diabetes mellitus+1

Recruiting

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational

The Netherlands

Participants:0–17 years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Zenagamtide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Mirikizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Gastric cancer

Recruiting

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Irinotecan Hydrochloride Trihydrate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Acute myocardial infarction

Recruiting

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adenosine
Sponsor:Corflow Therapeutics AG

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Veldhoven

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on cardiovascular conditions including heart failure, atrial fibrillation, and acute myocardial infarction. Research includes evaluation of new treatments for patients with preserved and reduced ejection fraction.

Heart Failure Management
Atrial Fibrillation Treatment
Atherosclerotic Disease

Several trials are investigating novel therapeutic approaches for cardiovascular disease prevention and treatment.

02 Oncology Studies

Comprehensive research in cancer treatment spanning multiple types including colorectal liver metastases, melanoma, and various blood cancers. Focus on innovative combination therapies and treatment optimization.

Colorectal Cancer
Blood Cancers
Melanoma Treatment

Trials evaluate both established and emerging therapeutic approaches for various cancer types.

03 Women's Health

Important research in reproductive health and women's medical conditions, including studies on contraception, uterine fibroids, and pregnancy-related disorders.

Contraceptive Development
Uterine Health
Pregnancy Complications

Clinical investigations focus on improving treatment options and outcomes for women's health conditions.

Back to the Netherlands All countries